argenex SE (NASDAQ:ARGX) Given Average Rating of “Moderate Buy” by Analysts

argenex SE (NASDAQ:ARGX) has received an average rating of “Moderate Buy” from the twenty-four ratings firms that are presently covering the stock, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $1,019.50.

Several equities research analysts have weighed in on ARGX shares. Zacks Research raised shares of argenex from a “strong sell” rating to a “hold” rating in a research report on Friday, February 20th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of argenex in a research report on Monday, April 20th. Wall Street Zen lowered argenex from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Wells Fargo & Company boosted their price objective on shares of argenex from $1,260.00 to $1,291.00 and gave the company an “overweight” rating in a research report on Monday, June 1st. Finally, Glj Research raised shares of argenex to a “strong-buy” rating in a research report on Friday, April 3rd.

Institutional Trading of argenex

Several large investors have recently bought and sold shares of ARGX. Abound Wealth Management boosted its position in argenex by 3,200.0% during the 4th quarter. Abound Wealth Management now owns 33 shares of the company’s stock valued at $28,000 after acquiring an additional 32 shares in the last quarter. Sound Income Strategies LLC purchased a new position in argenex during the fourth quarter valued at $28,000. Whipplewood Advisors LLC purchased a new position in argenex during the first quarter valued at $28,000. Ameriflex Group Inc. purchased a new position in argenex during the third quarter valued at $32,000. Finally, Sunbelt Securities Inc. purchased a new position in argenex during the third quarter valued at $36,000. 60.32% of the stock is owned by institutional investors.

argenex Price Performance

ARGX opened at $891.32 on Monday. The stock’s 50 day simple moving average is $794.90 and its 200 day simple moving average is $812.60. argenex has a 1 year low of $510.05 and a 1 year high of $934.62. The firm has a market cap of $55.43 billion, a price-to-earnings ratio of 39.68, a PEG ratio of 1.36 and a beta of 0.47.

argenex (NASDAQ:ARGX) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. The business had revenue of $1.31 billion for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%. As a group, sell-side analysts anticipate that argenex will post 26.25 EPS for the current year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.